It is well recognized that regulatory T cells (Tregs) are immunosuppressive, by which they prevent systemic autoimmunity throughout life. Beyond this stereotypical function, however, a growing body of evidence demonstrates that Tregs in distinct tissues, including the visceral adipose tissue, dystrophic muscle, the flu-infected lung, and wounded skin can acquire unique functions directed by their local environment. Tregs in these tissues can employ a wide variety of mechanisms to accumulate and acquire tissue-specific function, including conversion from conventional T cells, canonical T cell receptor (TCR)-dependent expansion and non-canonical, TCR-independent, cytokine-dependent expansion. Intriguingly, the niche-specific function of tissue Tregs can be independent of, and mutually exclusive of, their immunosuppressive capacity. Together, this recent literature reveals that Tregs can accumulate in discrete tissue sites through non-canonical mechanisms, and in response to niche-specific cues can acquire distinct functions, which distinguish them from their peripheral, lymphoid Treg counterparts. Other tissue Treg populations remain to be identified and characterized. Moreover, it is unknown whether other tissue Tregs rely on non-canonical mechanisms of accumulation, and exhibit functions distinct from the typical Treg immunosuppressive role. Tregs are known to accumulate in the CNS during infection, injury and inflammation. The CNS is an organ with distinctive architecture that maintains a regulated interaction with the peripheral immune system due to its critical function and poor regenerative capacity. While it is known that Tregs broadly protect against excessive tissue pathology in the diseased CNS, the origin, localization, function, mechanism of accumulation, and gene signature of CNS-infiltrating Tregs have not been studied, likely due to the challenge of isolating these rare cells and distinguishing them from circulating cells left over after perfusion. Here, we establish a safe model of CNS infection using encephalomyocarditis virus and employ a series of methods to locate, monitor and isolate CNS-infiltrating Tregs free from contamination from the circulation. We show that a distinct population of thymus-derived Tregs accumulates within the cerebrospinal fluid (CSF) of the EMCV-infected CNS, independently of lymph node priming. Tregs function in this unique niche to limit excessive tissue pathology. While CNS Tregs maintain expression of core Treg signature genes, including FoxP3, their global transcriptome is more similar to that of conventional T cells (Tcons) harvested from the infected CNS than to that of peripheral Tregs. Bioinformatics analysis reveals that genes shared by CNS Tcons and CNS Tregs are also shared by Tregs and Tcons from injured muscle and from the visceral adipose tissue of aged mice, indicating that tissue inflammation and injury, rather than viral infection per se, contribute to CNS Treg accumulation, function and phenotype. Additionally, we observe that CNS Treg accumulation during infection is associated with a simultaneous increase in meningeal/choroid plexus dendritic cells (m/chDCs), which are professional antigen presenting cells that localize to the gates of the CNS. Splenic cDC and peripheral lymphoid Treg homeostasis are linked, and both populations can be artificially increased by treatment with the DC-poietin and adjuvant, Ftlt3L. Therefore, we hypothesized that CNS Tregs and m/chDCs may also be linked and could also be manipulated by Flt3L treatment. Indeed, treatment with Flt3L in conjunction with EMCV infection results in enhanced CNS Treg and m/chDC accumulation, independent of Flt3 receptor expression on Tregs. In an effort to determine if dendritic cells mediate CNS Treg increase during infection, we turned to a DC-ablative mouse model in which all CD11c-expressing cells express the catalytic subunit of diphtheria toxin and are depleted. Surprisingly, while splenic cDCs are completely abrogated in these mice, a portion of m/chDCs persists, unaffected. Moreover, CNS Tregs accumulate normally in these mice during infection. This data suggests an unappreciated heterogeneity in m/chDCs, and indicates that those that remain unaffected in these mice may mediate CNS Treg accumulation during infection. While characterizing m/chDC heterogeneity, we found that m/chDCs comprise three distinct subsets with unknown potential. Whereas m/chDCs were previously considered to be a homogeneous, CD45hiB220-CD11c+MHCII+ population, we have found them to contain three subsets, distinguishable by IRF8 and FcR-γ expression. This finding paves the way for further study of the origin, localization, and division of labor between these three m/chDC subsets. In summary, our studies clarify the distinct compartmentalization, lymph node-independent accumulation, and inflammation-associated gene signature of CNS Tregs. Most importantly, these findings have implications for neuro-immune cross-talk, particularly at the interface of the CSF and brain parenchyma. That is, neural progenitors extend their apical domains into the CSF of the ventricles, and therefore may be subject to regulation by CSF-borne Tregs. Further, while many studies have focused on the differences between tissue Treg subsets, we find a core set of genes expressed by CNS Tregs, injured muscle Tregs and VAT Tregs. This data suggests that common mechanisms may be used for therapeutic manipulation of these cells.

Despite the actions of central tolerance during thymic selection, it is clear that the peripheral T cell repertoire contains significant numbers of self-reactive T cells. The immune system needs to curtail the risk of autoimmune disease by controlling the activity of these self-reactive T cells. Various mechanisms are in place to achieve this control (peripheral tolerance). Activation of CD4+ T cells requires two signals; engagement of the T cell receptor (TCR) with an appropriate peptide:MHC complex (signal 1), and the aggregate effect of multiple signals generated following ligation of costimulatory and coinhibitory molecules (signal 2). Both signals are required for the generation of a productive T cell response and both are provided by the professional antigen presenting cell, the dendritic cell (DC). T cells are fully activated upon receiving both signal 1 and 2, but are rendered tolerant when they receive only signal 1. This can be exploited therapeutically through the administration of peptides to induce tolerance in peptidereactive T cells. Administration of peptide with an adjuvant provides both signal 1 and 2, and leads to a sustained T cell response against the administered peptide (immunity). However, if the same peptide is administered in soluble form, only signal 1 is provided, leading to the establishment of T cell tolerance. The studies in this thesis explore the role of both signal 1 and signal 2 in peptide-induced T cell tolerance. Previous data from our laboratory have highlighted PD-1 and RANKL as costimulatory molecules which could play a role in peptide-induced T cell tolerance. Here we show that PD-1, an important coinhibitory molecule, plays a vital role in restraining peripheral T cell expansion under conditions leading to T cell immunity. However, in contrast to data from other studies, we demonstrate that PD-1 plays no role in the induction, establishment or maintenance of peptide-induced T cell tolerance. We show that the costimulatory receptor ligand pair RANK:RANKL plays a role in the balance between T cell tolerance and immunity; as administration of anti-RANKL was seen to potentiate both tolerance and immunity. We also explored the effect of altering the affinity of a peptide for MHC on the induction of peptide tolerance. We demonstrate that use of a peptide with a high-affinity for MHC induces tolerance via a novel, non-deletional mechanism of peptide-tolerance induction. Importantly, we show that the high-affinity peptide can form peptide- MHC complexes which persist in a biologically relevant form for fourteen days following peptide administration. We suggest that this leads to chronic stimulation of peptide-reactive T cells which promotes acquisition of a novel tolerant phenotype. Collectively the work described in this thesis demonstrates the important roles both signal 1 and 2 play in therapeutic-tolerance induction and how the qualitative and quantitative alteration of these signals can alter T cell fate and/or responsiveness.

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related compounds are well-recognized for their immunosuppressive activity, which is mediated through an intracellular receptor and transcription factor, aryl hydrocarbon receptor (AhR). Laboratory animals exposed to TCDD are less resistant to infection and have severely impaired humoral and cell-mediated immune responses. This dissertation addressed the hypothesis that exposure to TCDD disrupts early events during the activation of CD4⁺ T cells, leading to their premature loss from the spleen. Initially, ovalbumin (OVA)-specific CD4⁺ T cells from transgenic DO11.10 mice were used to monitor the effects of TCDD on activated antigen-specific T cells. A graft-versus-host (GVH) model, in which T cells from C57B1/6 (B6) mice are injected into C57B1/6 x DBA/2 Fl (Fl) mice, was used to study the role of AhR specifically in the T cells in response to TCDD. B6 donor T cells (from AhR[superscript +/+] or AhR[superscript -/-] mice) respond to DBA/2 antigens in Fl mice and a CD4-dependent CTL response is generated. In both models, exposure to TCDD significantly decreased the number of responding CD4⁺ T cells in the spleen beginning on day 4 after initiation of the response. Exposure to TCDD altered the phenotype of OVA-specific CD4⁺ T cells beginning on day 2 after immunization with OVA. These studies also suggested that apoptosis was not the primary mechanism responsible for the loss of CD4⁺ T cells from the spleen in TCDD-treated mice. Exposure to TCDD induced AhR-dependent changes in the phenotype of B6 donor CD4⁺ T cells such that a subpopulation of CD25⁺ cells was increased in TCDD-treated Fl mice, and these cells had in vitro functional characteristics consistent with regulatory T (Treg) cells. Exposure to TCDD increased the frequency of donor CD4⁺ T cells producing interleukin (IL)-2. In addition, increased expression of CD25 in TCDD-treated mice was correlated with increased signaling through the IL-2 receptor. However, IL-2 alone was not sufficient to mimic the potent immunosuppressive effects of TCDD. These results suggest that TCDD suppresses T cell immunity in part by inducing and/or expanding a subpopulation of Treg cells by a mechanism that may involve IL-2. / Graduation date: 2006

Thesis (PhD)--Montana State University--Bozeman, 2009. / Typescript. Chairperson, Graduate Committee: David Pascual. Includes bibliographical references (leaves 76-103).

Humoral immunity provides protection against subsequent infections. Antigen-specific, high-affinity, class-switched antibodies are produced by B cells through rounds of proliferation, B cell receptor rearrangement and selection in the germinal centres (GC). T cells play an essential and indispensable role in this process and in the recent years the term T follicular helper cells (TFH) was coined to describe this cell subset. The aim of my thesis is to investigate whether there is more than one type of T cells within the TFH population and whether it has important functional consequences. Firstly, I use sheep red blood cell immunisation (SRBC) and Salmonella enterica infection to show phenotypical differences between TFH expressing high and low level of surface molecule PD-1. In order to investigate the relationship between different TFH populations gene profiling was carried out on the microarray platform. Detailed transcriptome analysis revealed the discrete nature of isolated TFH cell subsets and provided an overview of their genetic landscape. Secondly, I have investigated the dependence of TFH subsets on cognate interactions with B cell in SRBC model by generating BM chimeras. I have demonstrated that generation of PD-1HI TFH, but not of PD-1LO TFH, depends on antigen presentation by B cells. Furthermore, I have shown that provision of wild-type but not MHC II knock-out B cells rescues PD-1HI formation in BM chimeras after SRBC immunisation. Finally, I have explored plasticity within TFH subsets and showed that none of the populations is in a terminally differentiated state, as they can convert into one another. Thirdly, experiments with S. enterica model revealed that the absence of PD- 1HI TFH is independent of the splenic architecture disruption present within the first week of the response. Surprisingly, co-immunisation studies showed that PD-1HI population is not only present but even enhanced in the group which received both SRBC and S. enterica when compared to single immunisations. The work presented in the thesis documents that there is a significant and previously unappreciated heterogeneity within TFH subset. This knowledge is important for designing optimal vaccine strategies and treating autoimmune diseases, as in both processes the antibody production plays a crucial role and its manipulation (either enhancing or blocking antibody production, respectively) can significantly improve clinical interventions.

published_or_final_version / Paediatrics / Doctoral / Doctor of Philosophy

No description available.

No description available.

No description available.

No description available.